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Objectives: The prognosis of patients with liver metastases of gastric cancer (LMGC) is dismal, but little
is known about prognostic factors in these patients; thus justification for surgical resection is still
controversial. The purpose of this study was to review recent outcomes of hepatectomy for LMGC and
to determine which patients represent suitable candidates for surgery by assessing surgical results and
clinicopathologic features.
Methods: Outcomes in 21 patients with LMGC who underwent hepatectomy between 1998 and 2007
were assessed. Isolated metastases and potential to perform a curative resection were requisite indi-
cations for surgery. Surgical outcome and clinicopathologic features of the hepatic metastases were
analysed.
Results: Overall 1-, 3- and 5-year survival rates after hepatic resection were 68%, 31% and 19%,
respectively; three patients survived for >5 years without recurrence. Univariate analysis revealed a
solitary metastasis, negative margin (R0) resection and the presence of a peritumoral fibrous capsule as
significant favourable prognostic factors. These characteristics were present in all of the three patients
who survived for >5 years.
Conclusions: Solitary metastases from gastric cancer should be treated surgically and confer a better
prognosis. Surgical resection should provide microscopically negative margins (R0). A new prognostic
factor, the presence of a pseudocapsule, may be associated with improved prognosis.
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Introduction
Although the effectiveness of liver resection for metastatic col-
orectal cancer has already been established,1–3 reports of hepatic
resection for liver metastases of gastric cancer (LMGC) are rare
and its efficacy is still controversial.4 In fact, a number of studies
have reported that the effects and benefits of hepatic resection in
either synchronous or metachronous gastric hepatic metastases
(GHM) are dubious.5 Surgical indications for liver metastases
from colorectal cancer have been expanded to include all
technically resectable metastases under four or more.6 Yet, the
surgical indications for LMGC must be carefully determined
because of the more severe biologic nature of this disease.7
Most patients with gastric cancer with concomitant liver
metastases are excluded as candidates for potential curative
surgery because of the presence of synchronous distant extrahe-
patic or locally advanced disease.8 In fact, GHM often represent
only part of a generalized spread of the primary tumour. Further-
more, very few patients with GHM are good candidates for liver
surgery because most patients have multiple, scattered, bilobar
lesions.9 Patients with isolated metastases are unusual and
accounted for 0.5% of patients in a series reported by Linhares
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et al.10 Baba et al. have shown that outcomes in patients who
undergo non-curative resection for advanced gastric cancer are
extremely poor.11 Several authors have reported limited experi-
ences of surgical resection of GHM in selected patients, with
5-year survival rates of 0–38%.12–14 Therefore, identifying the
patients who are most likely to benefit from surgical intervention
in the presence of GHM is clinically important. The aim of this
study was to review a single-institution experience to determine
the benefits of hepatic resection in patients with GHM and to
identify important prognostic factors.
Materials and methods
A total of 984 patients with gastric cancer (adenocarcinoma)
underwent surgery at the Department of Surgery, San Gerardo
Hospital, University of Milan Bicocca, between January 1998
and December 2007. Of these, 36 patients (3.7%) had synchro-
nous liver metastases and 31 patients (3.2%) developed metach-
ronous liver metastases after resection of the primary gastric
cancer. Of these 67 patients, 21 (31.3%) consecutive patients
underwent hepatic resection with intent to cure and were
selected for this study. Outcomes in these patients were retro-
spectively reviewed.
Criteria for resection of hepatic metastases from gastric cancer
were as follows: (i) no local relapse of the primary tumour in
metachronous metastases and curative resection of the primary
tumour and lymph node involvement proved or thought to be
technically possible in synchronous disease; (ii) no evidence of
disseminated disease after staging investigations, and (iii) ability
to achieve a microscopically margin-negative (R0) hepatic resec-
tion. Patients undergoing synchronous en bloc resections of
gastric cancer directly invading the liver were not included in this
study. Synchronous liver metastases were defined by detection
before or during surgery, or within 3 months of primary tumour
resection. The following clinicopathologic factors were analysed
and subgroups divided according to each variable were compared:
age; gender; status of serosal invasion; histologic differentiation of
the primary tumour; status of lymph node metastases; temporal
relationship of metastases with primary disease (synchronous or
metachronous); tumour distribution; size and number of liver
metastases; type of hepatic resection; surgical margin and com-
pleteness of the resection; presence of a pseudocapsule between
the metastasis and the liver parenchyma (defined as a wall of
fibrotic tissue between the tumour and the normal parenchyma);
histologic differentiation of the GHM, and vascular invasion
present within the GHM.
In each patient intraoperative liver ultrasound was performed
to assess the extent and number of hepatic lesions and their rela-
tionships to intrahepatic vascular and biliary structures. Preop-
erative workup included computed tomography and/or magnetic
resonance imaging. Liver surgical procedures were classified as
anatomic resection (segmentectomy and hemi-hepatectomy) or
limited resection (for all resections less extensive than segmentec-
tomy). Operative death was defined as death occurring within 30
days of the operation; in-hospital death was defined as any death
occurring before discharge. Morbidity included any type of com-
plication, whether surgical or non-surgical. Overall survival time
was measured from the date of hepatic resection to the date of
death from any cause. All patients were observed at intervals of
3–4 months during the first 2 years of the study and every 6
months or 12 months thereafter for 3 years.
Statistical analysis
Data were analysed using spss Version 19 (SPSS, Inc., Chicago, IL,
USA) for survival analysis, univariate analysis and Kaplan–Meier
curves. Comparisons of categorical and continuous variables were
performed using the chi-squared test and the Wilcoxon test,
respectively. Survival data were compared with the log rank test.
Variables with a P-value of <0.1 in the univariate analysis were
entered into a Cox regression analysis. A P-value of <0.05 was
considered to indicate statistical significance.
Results
Of the 21 patients, 14 were men. The median age of the patients
was 64 years (range: 44–89 years). Clinicopathologic characteris-
tics of the patients and data on primary tumours and metastases
are depicted in Table 1. Surgical procedures for primary gastric
cancer included 11 partial gastrectomies and 10 total gastrecto-
mies. The primary gastric tumour proved to be well to poorly
differentiated adenocarcinoma of the stomach in all patients.
Serosal invasion was present in eight patients. The median
maximum size of the metastatic tumours was 3.0 cm (range: 1.0–
8.5 cm). Tumour locations are reported in Table 1. Hepatic resec-
tions included four hemi-hepatectomies, five segmentectomies
(anatomical resections) and 12 wedge resections (non-anatomical
or limited resections). Blood transfusion was required in five
patients.
In the nine patients who underwent metachronous liver resec-
tion, the median interval between gastric resection and the diag-
nosis of hepatic metastasis [disease-free interval (DFI)] was 10
months (range: 5–15 months). These patients showed no evi-
dence of hepatic involvement at the time of surgery for the
primary tumour. In 19 patients the resection was classified as
curative (R0), whereas microscopically positive margins were
identified in two patients. With regard to pathologic features in
the peritumoral section of the metastatic lesion, fibrosis (fibrous
pseudocapsule) was found in 12 patients. In-hospital and 30-day
postoperative mortality was zero. The overall morbidity rate was
19.0% (four patients); complications comprised transient liver
failure, bile leakage, pleural effusion and wound infection in one
patient each. Median follow-up was 20 months (range: 6–90
months).
Overall 1-, 3- and 5-year survival rates were 68%, 31% and
19%, respectively. Median survival was 11 months. Rates of 1-,
3- and 5-year disease-free survival were 51%, 25% and 14%,
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respectively. Three patients remain alive and disease-free at >5
years after the surgical procedure. All three of these patients had a
solitary metastasis with a fibrous pseudocapsule. In the 19 patients
in whom R0 resection was achieved, 1-, 3- and 5-year survival
rates were 71%, 35% and 24%, respectively, whereas the margin-
positive procedures in two patients resulted in impaired survival
and both patients died within 1 year of resection. Recurrence
occurred in 14 patients. In 13 of these patients, disease recurred
within the liver. No patient underwent a second hepatic resection
for recurrent intrahepatic metastasis. The results of univariate
analysis identifying poor prognostic factors are depicted in
Table 1.
Discussion
In a review of the literature, hepatectomy was found to be indi-
cated in only 0.4–1.0% of gastric cancer patients with liver
metastases.4 Unfortunately, most hepatic metastases from gastric
adenocarcinoma are multiple, bilateral and combined with peri-
toneal or lymph node metastases, which directly invade adjacent
Table 1 Clinicopathologic characteristics and their prognostic significance
Variable Patients, n Proportion surviving, % P-value
1 year 3 years
Gastric carcinoma
Lymph node metastasis
N0–N1 10 60.1 48.3 0.11
N2 11 37.4 12.2
Serosal invasion
Absent 13 78.6 44.5 0.315
Present 8 62.4 27.8
Hepatic metastases
Solitary 12 70.3 56.7 0.044
Multiple 9 29.4 10.1
Lobar distribution
Unilobar 16 64.3 50.0
Bilobar 5 39.8 12.1 0.071
Tumour size
<5 cm 14 81.1 39.4 0.331
5 cm 7 50.1 37.5
Histologic differentiation
Good 8 80.2 41.6 0.144
Moderate, poor 13 67.3 30.0
Vascular invasion
Absent 13 75.2 44.1 0.211
Present 8 31.3 23.7
Fibrous pseudocapsule
Present 12 75.5 56.1 0.020
Absent 9 51.7 7.1
Surgery
Timing of hepatectomy
Synchronous 12 56.8 28.3 0.115
Metachronous 9 68.3 34.9
Resection margin
Negative 19 71.1 35.4 0.002
Positive 2 0.0 0.0
Type of surgery
Anatomic 9 75.6 33.2 0.846
Non-anatomic 12 70.6 31.8
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organs, thereby precluding a radical surgical approach.4 At spe-
cialized treatment centres, the proportion of surgery carried out
for LMGC is 7%, whereas that of hepatic resection for all types of
hepatic malignancies is 12%.15 Resectability does not seem to
be affected by the presence of metachronous or synchronous
metastases.16
The effectiveness of hepatic resection for GHM has not been
well defined. In addition, clinicopathologic factors that affect the
prognosis of patients with gastric cancer with hepatic metastases
have not been comprehensively identified. Nevertheless, the
presence of hepatic metastases is a statistically significant poor
prognostic factor for patients with gastric cancer.17
In recent series, 1-year survival rates have ranged from 42% to
90% and 5-year survival rates from 0% to 38% (Table 2). Most
studies concerning this issue come from Japan, where reported
longterm survival rates exceed 30% in some series.14,18 By contrast,
Zacherl et al. reported a study in which no patients survived 5
years after resection.15 Bines et al.19 reported one longterm survi-
vor in seven patients and other series have shown longterm sur-
vival rates of 11–19%. Although they are few, some longterm
survivors after hepatic resection have been reported. Therefore,
determining the indications for liver resection in the presence of
GHM is crucial.
The 5-year survival rate identified in this series is 19%. Three
longterm survival patients were identified, by contrast with
findings in another report from a Western country.15
None of the clinicopathologic features related to the primary
gastric cancer were predictors of survival. Ochiai et al.20 reported
that hepatic resection should only be attempted in patients with
synchronous or metachronous metastases in the absence of
serosal or microscopic lymphovascular invasion of the primary
tumour.21 Zacherl et al.15 reported that tumour localization in
primary gastric cancer was a marginally predictive negative factor
for the overall survival of patients. Tsujimoto et al.22 identified
gastric cancer tumour size as a predictor of poor survival.
In the current study, the presence of a solitary metastasis was a
positive predictor for survival. The number of metastatic nodules
in the liver has been reported to be an important prognostic factor
in previous studies. Okano et al.18 reported 3-year survival rates of
56% in patients with a single metastasis and 0% in patients with
multiple metastases. Koga et al.16 and Shirabe et al.21 reported
no longterm survivors in patients with multiple gastric liver
metastases. In a more recent study, Sakamoto et al.23 also reported
the value of a solitary lesion, adding to the evidence in support of
unilobar distribution as a good predictive factor for survival.
However, Saiura et al.24 reported two longterm survivors with
more than three metastases and concluded that, if curative resec-
tion (R0) can be achieved, hepatic resection should not be aban-
doned even in patients with multiple liver metastases. In fact, even
in this series R0 resection proved key to achieving good survival
and every effort should be made to achieve radical resection
with an adequate margin because this is the only factor on
which the surgeon can have any direct influence. Miyazaki et al.25
demonstrated significant differences in the size of the tumour-free
resection margin (<10 mm or >10 mm) in long- and short-term
survivors. Thelen et al.13 reported that a positive resection margin
should be considered a powerful determinant of poor outcome.
Nomura et al.26 showed that the recurrence rate in the remnant
liver was higher in patients with a surgical margin of <5 mm.
Isono et al.27 reported that micrometastases around the macro-
scopic tumour were found more frequently in hepatic metastases
from gastric cancer than in those from colorectal cancer. Accord-
ing to the pattern of recurrence, relapse developed most com-
monly in the liver (median: 70%; range: 63.6–83.3%), indicating
that relapse monitoring should focus on the remaining liver. A
sensible strategy for improving survival would involve close obser-
vation for a second relapse in the liver and the provision of adju-
vant chemotherapies after surgery. In this series, only one patient
received a postoperative hepatic arterial infusion; this patient
survived 38 months. In terms of adjuvant therapy, however, no
conclusions can be based on these data.
The timing of hepatic resection has been reported to be a sig-
nificant prognostic factor and some papers have reported syn-
chronous hepatectomy as a significant poor prognostic factor.5,19
Nevertheless, an analysis of the data reported in the recent litera-
ture showed that 22 of 48 5-year survivors underwent synchro-
nous hepatectomy.23 Thus, synchronous hepatectomy should not
be a contraindication for hepatic resection. The data reported
in the present study show comparable median survival rates
in patients with synchronous and metachronous lesions. With
regard to perioperative morbidity, the current results confirm the
observation of Bines et al.19 that synchronous liver resection
carries a higher risk. Moreover, the DFI between gastric and
hepatic resection has been reported to represent a prognostic
factor. Fujii et al.28 showed that a DFI of >1 year had a significant
survival advantage as a result of the slow-growing nature of this
tumour. However, this trend was not confirmed in the present
study.
The aggregation of lymphocytes enclosing the metastatic
tumour was reported as a good prognostic factor by Fujii et al.28
This may be explained by the favourable action of tumour-
infiltrating lymphocytes (TILs) in preventing tumour extension in
gastric cancer patients.29 Okano et al.18 demonstrated that the
presence of fibrous pseudocapsules around liver metastases is a
promising indicator of a better prognosis and is closely associated
with patient survival. The formation of a pseudocapsule should be
considered as a protective immunoinflammatory reaction against
the metastastic nodule and as representing the host defence
reaction of creating a wall to stop tumour diffusion.
Conclusions
Although some authors hold the view that metastatic gastric
cancer represents a systemic disease and indicates a diffuse cancer,
and that surgery has no role in its treatment, a considerable pro-
portion of patients in the present as well as former series were
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found to be tumour-free at >5 years after liver resection. The
present authors believe that surgery may provide a benefit
and should be part of a multidisciplinary approach in patients
with LMGC.31 Solitary metastases, the ability to achieve R0 resec-
tion, and the presence of a pseudocapsule are determinants of
improved survival.
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